Biotechnology Consultant: Molecular Biology, Gene Expression, Expert Witness, Patents and Licensing

Technical Consultant #1546

Molecular target identification and validation.
ELISA and cell-based assays.
Small molecule and biologics.
Cell culture, gene transfer and expression.
Virology, oncology, autoimmune disease drug discovery.
Business planning, opportunity scouting and analysis, strategy formulation.
Evaluation in-licensing pharma and biophamaceutical opportunities.
Patent drafting and expert witness on matters related to cellular and molecular biology.

Undisclosed University, Business Development Manager, 2015 - Present

University of Missouri, Columbia, MO. Sr. Licensing and Bus Dev Associate, 2009 - 2015

Independent Consultant, 2008 - Present

Technical consultant for patent law firm achieving in-depth novelty and FTO analysis for biotech clients as well as time-critical drafting of new patent applications.
Identification of companies with clinical programs in specific field of interest as prelude to targeted business development activities.

Keel Pharmaceuticals, Inc., Director of Research, 2005 - 2008

Directed start-up biopharmaceutical company's research efforts resulting in identification and characterization of lead monoclonal antibody for autoimmune disease treatment.
Established laboratory operations and used focused, coordinated activities among lab staff, collaborators, consultants, advisors and vendors to achieve goals on time.

Biosynthecore, LLC, Vice President Business Development, 2003 - 2005

Key leadership position for biotech startup specializing in allergy test and biocatalytic based manufacturing.
Co-founder with focused role on market analysis and technology license scouting and acquisition.

Pharmacia (Pfizer), Science Fellow and Senior Research Advisor, 2000 - 2003

Managed research budgets and staff for the pharmaceutical research and development division.
Recognized as scientific leader. Collaborated with licensing department to identify new research and commercial opportunities in oncology.
Evaluated over 200 in-licensing opportunities and identified new opportunities that complemented existing programs that helped focus oncology strategy.
Streamlined and standardized scouting efforts to achieve more harmonious information regarding new in-licensing opportunities resulting easier analysis.
Identified new oncology target from transcription profiling effort and advanced toward final validation in support of new monoclonal antibody project initiative.

Monsanto - G.D. Searle, 1984 - 2000

Science Fellow, group leader and project leader for international collaboration with a Japanese pharmaceutical company.
Drug discovery experience in oncology and antiviral drug development.
Identified and implemented new collaboration in cancer vaccine and established partner resulting in novel approach to stimulate the immune system.
Invented new approach to cytomegalovirus (CMV) antiviral screening resulting in 300% increase in throughput.
Invented new mammalian expression system distributed around the world that enables over one hundred discovery projects with minimal personnel involvement.

Academic and Professional Affiliations

Publications and Patents